



(51) International Patent Classification:

C07C 215/42 (2006.01) *A61P 9/00* (2006.01)
A61K 31/133 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:

PCT/US2014/017534

(22) International Filing Date:

21 February 2014 (21.02.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/767,531 21 February 2013 (21.02.2013) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543-4000 (US).(72) Inventors: DHAR, T. G. Murali; c/o Bristol-Myers
Squibb Company, Route 206 & Province Line Road, Prin-
ceton, New Jersey 08543 (US). XIAO, Hai-Yun; c/o Bris-
tol-Myers Squibb Company, Route 206 & Province Line
Road, Princeton, New Jersey 08543 (US). DYCKMAN,
Alaric J.; c/o Bristol-Myers Squibb Company, Route 206
& Province Line Road, Princeton, New Jersey 08543 (US).
CHAN, Eric J.; c/o Bristol-Myers Squibb Company, 1
Squibb Drive, New Brunswick, New Jersey 08903 (US).
DABROS, Marta; c/o Bristol-Myers Squibb Company,
Route 206 & Province Line Road, Princeton, New Jersey
08543 (US). ROBERTS, Daniel Richard; c/o Bristol-My-
ers Squibb Company, 1 Squibb Drive, New Brunswick,
New Jersey 08903 (US).(74) Agents: GREENBLATT, Gary D. et al.; Bristol-Myers
Squibb Company, P.O. Box 4000, Princeton, New Jersey
08543-4000 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: BICYCLIC COMPOUNDS



(I)

(57) Abstract: Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is -OH or -OP(O)(OH)₂. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P₁, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.



(88) Date of publication of the international search report:
23 October 2014